# OPTION-EMEA Clinical Trial

Study · id `cardio:ct-nct07349121` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07349121](<https://clinicaltrials.gov/study/NCT07349121>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07349121

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT07349121. Allocation not applicable; no masking; primary purpose other. Start 2026-06-18 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Not applicable
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT07349121, source copy `cardio:ctgov-nct07349121-2026-10-27`, retrieved 2026-10-31)
- Started: 2026-06-18 (actual) (ClinicalTrials.gov record NCT07349121, source copy `cardio:ctgov-nct07349121-2026-10-27`, retrieved 2026-10-31)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07349121, source copy `cardio:ctgov-nct07349121-2026-10-27`, retrieved 2026-10-31)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07349121, source copy `cardio:ctgov-nct07349121-2026-10-27`, retrieved 2026-10-31)
- Countries: Belgium; Croatia; France; Italy; Spain (ClinicalTrials.gov record NCT07349121, source copy `cardio:ctgov-nct07349121-2026-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07349121-2026-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: OPTION-EMEA Clinical Trial
- Acronym: OPTION-EMEA
- Condition: Atrial Fibrillation (AF)
- Condition: Stroke Prevention in Patients With Atrial Fibrillation
- Condition: Left Atrial Appendage Closure
- Condition: Pulsed Field Ablation
- Condition: Atrial Fibrillation Ablation Procedure
- Condition: Concomitant Procedures
- Intervention (Device): Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case
- Intervention (Procedure): Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: cc5c33d6c5fb58744273455d30e0d543c3f6c14a9e31f5c04521c2b8fc523a35
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
